drugset
drugset / Trial / NCT07139548

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

NCT07139548 ↗

Phase 3 Not yet recruiting 600 enrolled Guangdong Raynovent Biotech Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.

Timeline

Start
2025-08-31
Primary completion
2026-12-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RAY1225 Unknown 6 mg Subcutaneous
Subject RAY1225 Unknown 9 mg Subcutaneous
Comparator Semaglutide Peptide 1 mg Subcutaneous

Indications

type 2 diabetes mellitus